Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 27 of 110 Updated Nov 17, 2026

GHRP-2

Pralmorelin · KP-102

JAPAN-APPROVED DIAGNOSTIC · GHRP; GHRELIN RECEPTOR AGONIST

▓ 148 indexed citations across PubMed (139), EuropePMC (9).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

148 citations across 6 tiers

Tap any tier to jump to that section of the bibliography.

Background

Pralmorelin is a growth hormone secretagogue (GHS) used as a diagnostic agent that is marketed by Kaken Pharmaceutical in Japan in a single-dose formulation for the assessment of growth hormone deficiency (GHD).

→ Wikipedia

Mechanism of action

GHS-R1a agonist; strong GH release

Researched effects

Strong GH release; some appetite increase; lean mass

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

100-300 mcg SC 1-3x daily

Known concerns

Cortisol/prolactin increase; hunger; water retention

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Systematic review of undeclared prohibited substances and pharmacological adulterants in dietary supplements: prevalence, detection, and risks in sport.

    2026 — SYSTEMATIC REVIEWS · AUTHORITY 84.5

  2. Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp.

    The Journal of clinical endocrinology and metabolism · 2009 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 76.9

  3. Aromatase and 5alpha-reductase inhibition during an exogenous testosterone clamp unveils selective sex steroid modulation of somatostatin and growth hormone secretagogue actions in healthy older men.

    The Journal of clinical endocrinology and metabolism · 2009 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 76.9

  4. Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp.

    The Journal of clinical endocrinology and metabolism · 2009 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 76.9

  5. Determinants of dual secretagogue drive of burst-like growth hormone secretion in premenopausal women studied under a selective estradiol clamp.

    The Journal of clinical endocrinology and metabolism · 2005 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 76.5

  6. Short-term testosterone supplementation relieves growth hormone autonegative feedback in men.

    The Journal of clinical endocrinology and metabolism · 2004 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 76.4

  7. Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues.

    The Journal of clinical endocrinology and metabolism · 1998 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 76.0

  8. Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone.

    The Journal of clinical endocrinology and metabolism · 1998 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 76.0

  9. Differential pulsatile secretagogue control of GH secretion in healthy men.

    American journal of physiology. Regulatory, integrative and comparative physiology · 2013 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 73.3

  10. Secretagogue type, sex-steroid milieu, and abdominal visceral adiposity individually determine secretagogue-stimulated cortisol secretion.

    European journal of endocrinology · 2010 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 73.0

Full citation library

Year distribution

Systematic Reviews

1
  1. 1.

    Al-Saad N, Aljaal S, Alessa J, Santhosh ME. · 2026 · PMID 41908212

    <h4>Introduction</h4>The proliferation of dietary supplement use among athletes has heightened concerns over inadvertent doping due to contamination with substances prohibited by the World Anti-Doping Agency (WADA) and other undeclared pharmacological adulterants. This systematic review synthesizes empirical evidence on the prevalence, detection, and risks associated with sport supplement contamination. The review framework encompassed both explicitly prohibited doping agents and potent metaboli…

Randomised Controlled Trials

20
  1. 2.

    Van den Berghe G, Baxter RC, Weekers F, Wouters P, et al. · Clinical endocrinology · 2002 · PMID 12030918

    Central hyposomatotrophism, hypothyroidism and hypogonadism are present concomitantly in men with prolonged critical illness. This study evaluated the impact of combined treatment with GH-releasing peptide-2 (GHRP-2), TRH and GnRH for 5 days compared with GHRP-2 + TRH and with GHRP-2 alone. Thirty-three men with prolonged critical illness participated at baseline compared to 50 age- and body mass index (BMI)-matched controls. Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (…

  2. 3.

    Norman C, Miles J, Bowers CY, Veldhuis JD · American journal of physiology. Regulatory, integrative and comparative physiology · 2013 · PMID 23485864

    Pulsatile growth hormone (GH) secretion putatively reflects integrated regulation by GH-releasing hormone (GHRH), somatostatin (SST), and GH-releasing peptide (GHRP). GHRH and SST secretion is itself pulsatile. However, how GHRH and SST pulses act along with GHRP to jointly determine pulsatile GH secretion is unclear. Moreover, how testosterone (T) modulates such interactions is unknown. These queries were assessed in a prospectively randomized, placebo-controlled double-blind cohort comprising…

  3. 4.

    Veldhuis JD, Bowers CY · The Journal of clinical endocrinology and metabolism · 2009 · PMID 19351731

    Sex steroids are prominent regulators of pulsatile GH secretion. An experimentally controlled sex-steroid milieu will permit detection of nonsteroidal factors that determine GH secretion. Eleven young (age, 24 +/- 0.99 yr) and 11 older (64 +/- 2.4 yr) men participated in the study. The study was conducted at a tertiary medical center. The study consisted of GnRH-agonist down-regulation of the gonadal axis followed by fixed-dose testosterone (T) replacement (leuprolide/T clamp) and consecutive in…

  4. 5.

    Veldhuis JD, Bowers CY · American journal of physiology. Endocrinology and metabolism · 2009 · PMID 19240251

    Age, sex steroids, and abdominal-visceral fat (AVF) jointly affect pulsatile growth hormone (GH) secretion. Pulsatile GH secretion in turn is controlled by GH-releasing hormone (GHRH), GH-releasing peptide (GHRP), and somatostatin. Marked stimulation of pulsatile GH secretion is achieved via GHRH-GHRP synergy. Nonetheless, how key modulators of GH secretion, such as age, sex steroids, and body mass index, modify GHRH-GHRP synergy is not known. The present strategy was to 1) infuse GHRH and GHRP-…

  5. 6.

    Hu R, Wang Z, Peng Q, Zou H, et al. · PloS one · 2016 · PMID 26894743

    The objective of this study was to investigate the effects of growth hormone-releasing peptide-2 (GHRP-2) and cysteamine (CS) administration on growth performance in yaks with growth retardation and try to elucidate its regulatory mechanisms. Trial 1, thirty-six 1-year-old Qinghai high plateau yaks (body weight 38-83.2 kg) were randomly chosen for body weight and jugular blood samples collection. The relationship between body weight and serum GHRH (P < 0.05, R = 0.45), GH (P < 0.05, R = 0.47), I…

  6. 7.

    Arvat E, Di Vito L, Lanfranco F, Broglio F, et al. · Journal of endocrinological investigation · 1999 · PMID 10195374

    Hexarelin (HEX) and GHRP-2 are two synthetic hexapeptides, superanalogs of GHRP-6, belonging to GH secretagogue (GHS) family. GHS act via specific receptors at both the pituitary and the hypothalamic level to stimulate GH release both in animals and in humans. However, GHS also possess significant PRL- and ACTH/cortisol-releasing activity. Tyr-Ala-HEX as well as Tyr-Ala-GHRP-6 are, in turn, synthetic octapeptides generally used to perform binding studies because of their easy iodination. However…

  7. 8.

    Veldhuis JD, Evans WS, Iranmanesh A, Weltman AL, et al. · The Journal of clinical endocrinology and metabolism · 2004 · PMID 15001624

    The present study tests the postulate that testosterone (Te) stimulates GH secretion, in part, by attenuating autonegative feedback. To this end, 13 healthy men (ages 43-71 yr) received three consecutive weekly im injections of placebo (Pl) (n = 7) or Te (200 mg) (n = 6) in a prospectively randomized, double-blind, parallel-cohort design. An iv pulse of saline or recombinant human (rh)GH (3 micro g/kg.6 min) was infused 2 h before bolus saline or GH-releasing peptide (GHRP)-2 (1 micro g/kg) in t…

  8. 9.

    Veldhuis JD, Keenan DM, Bowers CY · American journal of physiology. Regulatory, integrative and comparative physiology · 2007 · PMID 17686882

    Estradiol (E(2)) drives growth hormone (GH) secretion via estrogen receptors (ER) located in the hypothalamus and pituitary gland. ERalpha is expressed in GH releasing hormone (GHRH) neurons and GH-secreting cells (somatotropes). Moreover, estrogen regulates receptors for somatostatin, GHR peptide (GHRP, ghrelin), and GH itself, while potentiating signaling by IGF-I. Given this complex network, one cannot a priori predict the selective roles of hypothalamic compared with pituitary ER pathways. T…

  9. 10.

    Van den Berghe G, Wouters P, Bowers CY, de Zegher F, et al. · European journal of endocrinology · 1999 · PMID 10037246

    During prolonged critical illness, nocturnal pulsatile secretion of GH, TSH and prolactin (PRL) is uniformly reduced but remains responsive to the continuous infusion of GH secretagogues and TRH. Whether such (pertinent) secretagogues would synchronize pituitary secretion of GH, TSH and/or PRL is not known. We explored temporal coupling among GH, TSH and PRL release by calculating cross-correlation among GH, TSH and PRL serum concentration profiles in 86 time series obtained from prolonged criti…

  10. 11.

    Van den Berghe G, de Zegher F, Baxter RC, Veldhuis JD, et al. · The Journal of clinical endocrinology and metabolism · 1998 · PMID 9467533

    The catabolic state of prolonged critical illness is associated with a low activity of the thyrotropic and the somatotropic axes. The neuroendocrine component in the pathogenesis of these low activity states was assessed by investigating the effects of continuous intravenous infusions of TRH, GH-releasing peptide-2 (GHRP-2), and GHRH. Twenty adult patients, critically ill for several weeks, were studied during two consecutive nights. They had been randomly allocated to one of three combinations…

  11. 12.

    Van den Berghe G, Wouters P, Carlsson L, Baxter RC, et al. · The Journal of clinical endocrinology and metabolism · 1998 · PMID 9745404

    Prolonged critical illness is characterized by feeding-resistant wasting of protein, whereas reesterification, instead of oxidation of fatty acids, allows fat stores to accrue and associate with a low-activity status of the somatotropic and thyrotropic axis, which seems to be partly of hypothalamic origin. To further unravel this paradoxical metabolic condition, and in search of potential therapeutic strategies, we measured serum concentrations of leptin; studied the relationship with body mass…

  12. 13.

    Veldhuis JD, Mielke KL, Cosma M, Soares-Welch C, et al. · The Journal of clinical endocrinology and metabolism · 2009 · PMID 19088159

    How endogenous testosterone (Te), 5alpha-dihydrotestosterone (DHT), and estradiol (E(2)) regulate pulsatile GH secretion is not understood. Conversion of Te to androgenic (Te-->DHT) or estrogenic (Te-->E(2)) products directs GH secretion. SUBJECTS AND LOCATION: Healthy older men (N = 42, ages 50-79 yr) participated at an academic medical center. We inhibited 5alpha-reduction with dutasteride and aromatization with anastrozole during a pharmacological Te clamp and infused somatostatin (SS), GHRH,…

  13. 14.

    Iranmanesh A, Bowers CY, Veldhuis JD · European journal of endocrinology · 2010 · PMID 20299490

    While androgens and estrogens control glucocorticoid secretion in animal models, how the sex-steroid milieu determines cortisol secretion in humans is less clear. To address this issue, cortisol was measured in archival sera obtained at 10-min intervals for 5 h in 42 healthy men administered double placebo, placebo and testosterone, testosterone and dutasteride (to block 5alpha-reductases type I and type II), or testosterone and anastrozole (to block aromatase) in a double-blind, placebo-control…

  14. 15.

    Veldhuis JD, Hudson SB, Erickson D, Bailey JN, et al. · American journal of physiology. Endocrinology and metabolism · 2009 · PMID 19470834

    Growth hormone (GH) secretion is subject to complex regulation. How pre- and postmenopausal age (PRE, POST), estradiol (E(2)) availability, and abdominal visceral fat (AVF) jointly affect peptidyl-secretagogue drive of GH secretion is not known. To this end, healthy PRE (n = 20) and POST (n = 22) women underwent a low- vs. high-E(2) clamp before receiving a continuous intravenous infusion of GH-releasing hormone (GHRH) or GH-releasing peptide (GHRP-2). According to analysis of covariance, PRE an…

  15. 16.

    Van den Berghe G, de Zegher F, Bowers CY, Wouters P, et al. · Clinical endocrinology · 1996 · PMID 8949573

    Protein hypercatabolism and preservation of fat depots are hallmarks of critical illness, which is associated with blunted pulsatile GH secretion and low circulating IGF-I, TSH, T4 and T3. Repetitive TRH administration is known to reactivate the pituitary-thyroid axis and to evoke paradoxical GH release in critical illness. We further explored the hypothalamic-pituitary function in critical illness by examining the effects of GH-releasing hormone (GHRH) and/or GH-releasing peptide-2 (GHRP-2) and…

  16. 17.

    Moreno-Reyes R, Kerkhofs M, L'Hermite-Balériaux M, Thorner MO, et al. · The American journal of physiology · 1998 · PMID 9612233

    A complex interrelationship exists between sleep and somatotropic activity. In humans, intravenous injections of growth hormone-releasing hormone (GHRH) given during sleep consistently stimulate slow-wave (SW) sleep, particularly when given in the latter part of the night. In the present study, the possible somnogenic effects induced under similar conditions by GH-releasing peptide (GHRP) were investigated in seven young healthy men. Bolus intravenous injections of GHRP-2 (1 microgram/kg body wt…

  17. 18.

    Veldhuis JD, Keenan DM, Bailey JN, Miles JM, et al. · European journal of endocrinology · 2009 · PMID 19458139

    Somatostatin (SS), GHRH, GH-releasing peptide (GHRP), and the sex-steroid milieu regulate GH secretion. To test whether GHRH and GHRP remain effective secretagogs in the face of short-term hypogonadism. Prospective, randomized double-blind. Healthy young men (n=24) received a GnRH agonist twice 3 weeks apart followed by placebo (n=13, Pl) or testosterone (n=11, testosterone) addback. were then given consecutive i.v. infusions of l-arginine (to restrain SS outflow) and a maximally effective dose…

  18. 19.

    Veldhuis JD, Keenan DM, Bailey JN, Adeniji AM, et al. · The Journal of clinical endocrinology and metabolism · 2009 · PMID 19351723

    Sex steroids influence GH secretion in complex ways. Analyses in a low sex-steroid milieu will help unveil the effects of age and other nonsteroidal regulators on GH secretion. The study was conducted in a tertiary medical center. The study group included 13 healthy young men and 12 healthy older men. We used GnRH agonist-induced down-regulation of testosterone and estradiol secretion, followed by consecutive infusion of l-arginine and GHRH or GHRP-2, to test secretagogue efficacies. We measured…

  19. 20.

    Erickson D, Keenan DM, Farhy L, Mielke K, et al. · The Journal of clinical endocrinology and metabolism · 2005 · PMID 15613434

    The present study tests the hypothesis that estradiol (E(2)), compared with placebo (Pl), amplifies combined-secretagogue stimulation of GH secretion in premenopausal women studied at comparable IGF-I and testosterone concentrations. To this end, 13 women underwent GnRH agonist-induced gonadal down-regulation followed by graded transdermal addback of E(2) or Pl and randomly ordered iv infusions of saline or paired secretagogues on separate morning fasting. GH secretion was assessed by frequent b…

  20. 21.

    Meacham LR, Culler FL, Abdul-Latif H, Sullivan KM, et al. · Metabolism: clinical and experimental · 1999 · PMID 10337858

    Children who require long-term glucocorticoid treatment often demonstrate poor growth. Growth hormone (GH) secretion is decreased during glucocorticoid treatment, and this decrease may be due to a relative excess of the hypothalamic hormone somatostatin (SRIF). GH-releasing peptide-2 (GHRP-2) is a GH secretagogue that acts via multiple mechanisms at multiple sites. One of its proposed mechanisms is the ability to bypass SRIF blockade of GH secretion. We measured the ability of GHRP-2 to release…

Clinical Trials

10
  1. 22.

    Bowers CY, Granda-Ayala R · Journal of pediatric endocrinology & metabolism : JPEM · 1996 · PMID 8887169

    Studies with chronic GHRP-2 or GHRH administration were performed to demonstrate and better understand the interrelationships between GHRP-2, GHRH and SRIF. Normal younger and older men and women received chronic GHRP-2, GHRH or GHRP-2 + GHRH for 7-30 days. It was demonstrated that chronic administration of either GHRP-2 or GHRH could convert an additive GHRP-2 + GHRH GH response to a synergistic one. In addition, the type of synergistic response induced by chronic GHRP-2 versus GHRH was differe…

  2. 23.

    Wideman L, Weltman JY, Patrie JT, Bowers CY, et al. · American journal of physiology. Regulatory, integrative and comparative physiology · 2000 · PMID 11004017

    We investigated the ability of exercise, a multipathway, potent, physiological stimulus for GH release, to alter the synergistic interaction of L-arginine (A) and GH-related peptide (GHRP)-2 (G) observed at rest and the ability of gender to further modulate this putative interaction. Subjects (9 men and 9 early follicular phase women) completed 30 min of constant load aerobic exercise in combination with intravenous infusions of saline (S), A (30 g over 30 min), G (1 microg/kg bolus), or both (A…

  3. 24.

    Veldhuis JD, Cosma M, Erickson D, Paulo R, et al. · The Journal of clinical endocrinology and metabolism · 2007 · PMID 17405836

    Studies of how aging attenuates GH secretion are confounded by differences in sex-steroid milieus, abdominal visceral fat mass (AVF), and IGF-I concentrations and limited in interpretability by the use of pharmacological doses of secretagogues. In a controlled estrogenic milieu, near-physiological secretagogue drive will unmask distinct influences of age, AVF, and IGF-I on GH secretion. The study was conducted at an academic medical center. Subjects included 10 healthy pre- (PRE) and 10 postmeno…

  4. 25.

    Chihara K, Shimatsu A, Hizuka N, Tanaka T, et al. · European journal of endocrinology · 2007 · PMID 17609397

    The international, first-line diagnostic test for adult GH deficiency is the insulin tolerance test (ITT), which is contraindicated in some patients due to severe adverse events. Alternatives such as GH-releasing hormone combined with arginine or GH-releasing peptides (GHRP) have been proposed. We validated the use of GHRP-2 for diagnosing adult GH deficiency (GHD). Seventy-seven healthy subjects and 58 patients with peak GH<3 microg/l by ITT were enrolled. After overnight fasting, a 100 microg…

  5. 26.

    Mericq V, Cassorla F, Salazar T, Avila A, et al. · The Journal of clinical endocrinology and metabolism · 1998 · PMID 9661608

    Stimulation of pituitary GH secretion with administered GHRH can be effective therapy for those GH deficient (GHD) patients whose disorder results from insufficient endogenous GHRH secretion. We have previously shown that most such patients also respond acutely to the GH-releasing peptides (GHRP's), which have a different mechanism of action from GHRH, with release of GH. In this study we tested whether the GH response to a newer GHRP, GHRP-2, would be sustained over time. Six prepubertal childr…

  6. 27.

    Pihoker C, Badger TM, Reynolds GA, Bowers CY · The Journal of endocrinology · 1997 · PMID 9390009

    Growth hormone-releasing peptide (GHRP)-2 is a synthetic six amino acid peptide that is a potent GH secretagogue. Although it shares no structural homology with GH-releasing hormone, in clinical studies its actions on the pituitary release of GH are similar. It is effective when administered orally and intranasally. For children with GH deficiency, such noninvasive treatments are most desirable and in need of development. Fifteen children with short stature participated in this study. All of the…

  7. 28.

    Arimura H, Hashiguchi H, Yamamoto K, Shinnakasu A, et al. · Endocrine journal · 2016 · PMID 27020037

    The aim of this study was to evaluate the ability of the growth hormone-releasing peptide-2 (GHRP-2) test to clinically diagnose hypothalamo-pituitary-adrenal (HPA) axis failure. We performed an insulin tolerance test (ITT), CRH stimulation test, and GHRP-2 test on 47 patients suspected of having a hypothalamo-pituitary disorder. Patients with pituitary disorders had significantly lower ACTH responses to the GHRP-2 test compared to patients with hypothalamic disorders and the control group. In c…

  8. 29.

    Pihoker C, Middleton R, Reynolds GA, Bowers CY, et al. · The Journal of clinical endocrinology and metabolism · 1995 · PMID 7559885

    GH secretion is primarily regulated by the hypothalamic-releasing hormones GHRH and somatostatin. Additionally, several neurotransmitters act at the hypothalamus and pituitary to modulate GH release. The agents commonly used in clinical practice to diagnose GH deficiency, such as arginine, insulin and L-dopa, act through the neural GH network. Many children with a poor GH response to conventional agents have a significant serum GH response to iv GHRH. GH-releasing peptides (GHRPs) are synthetic…

  9. 30.

    Pihoker C, Kearns GL, French D, Bowers CY · The Journal of clinical endocrinology and metabolism · 1998 · PMID 9543135

    Administration of GH-releasing peptide-2 (GHRP-2) represents a potential mode of therapy for children of short stature with inadequate secretion of GH. Requisite information to determine the dosing route and frequency for GHRP-2 consists of the pharmacokinetics (PK) and pharmacodynamics (PD) for this compound, neither of which have been previously evaluated in children. The purpose of this study was to characterize the PK and PD of GHRP-2 in children with short stature. Ten prepubertal children…

  10. 31.

    Salvatori R, Serpa MG, Parmigiani G, Britto AV, et al. · Journal of endocrinological investigation · 2006 · PMID 17114911

    GH secretion by the pituitary is the result of the balance between the stimulatory effect of GHRH and the inhibitory effect of SS. Patients with mutations in GHRH receptor (GHRH-R) gene (GHRH-R) offer a unique model to study the mechanism of action of different GH secretion stimuli. In the past, we have demonstrated a small but significant GH response to a GH secretagogue (GHRP-2) in a homogenous cohort of patients with severe GH deficiency (GHD) due to a homozygous null mutation in GHRH-R (IVS1…

Reviews

14
  1. 32.

    Drugs in R&D · 2004 · PMID 15230633

    Pralmorelin [GPA 748, GHRP 2, growth hormone-releasing peptide 2, KP-102 D, KP 102 LN] is an orally active, synthetic growth hormone-releasing peptide from a series of compounds that were developed by Polygen in Germany and Tulane University in the US. Researchers at Tulane University led by Dr Cyril Bowers synthesised a series of small highly active peptides ranging in size from 3-5 amino acids or partial peptides that were suitable for a variety of administration formats (subcutaneous, buccal,…

  2. 33.

    Ghigo E, Arvat E, Muccioli G, Camanni F · European journal of endocrinology · 1997 · PMID 9186261

    Growth hormone-releasing peptides (GHRPs) are synthetic, non-natural peptides endowed with potent stimulatory effects on somatotrope secretion in animals and humans. They have no structural homology with GHRH and act via specific receptors present either at the pituitary or the hypothalamic level both in animals and in humans. The GHRP receptor has recently been cloned and, interestingly, it does not show sequence homology with other G-protein-coupled receptors known so far. This evidence strong…

  3. 34.

    Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, et al. · Translational andrology and urology · 2020 · PMID 32257855

    Male hypogonadism is an increasingly prevalent clinical condition that affects patients' quality of life and overall health. Obesity and metabolic syndrome can both cause and result from hypogonadism. Although testosterone remains the gold standard for hypogonadism management, its benefits are not always conserved across different populations, especially with regards to changes in body composition. Partially in response to this, growth hormone secretagogues (GHS) have emerged as a potential nove…

  4. 35.

    Fukuda I, Hizuka N, Muraoka T, Ichihara A · Neurologia medico-chirurgica · 2014 · PMID 25070016

    The clinical syndrome of adult growth hormone deficiency (AGHD) was widely recognized in the 1980s. In this review, we first describe the clinical features and diagnosis of AGHD and then state the effects of growth hormone (GH) therapy for these patients. The main characteristics of AGHD are abnormal body composition, dyslipidemia, insulin resistance, and an impaired quality of life (QoL) due to decreased psychological well-being. For diagnosing AGHD, the international consensus guidelines have…

  5. 36.

    Camanni F, Ghigo E, Arvat E · Frontiers in neuroendocrinology · 1998 · PMID 9465289

    Growth hormone-releasing peptides (GHRPs) are a series of hepta (GHRP-1)- and hexapeptides (GHRP-2, GHRP-6, Hexarelin) that have been shown to be effective releasers of GH in animals and humans. More recently, a series of nonpeptidyl GH secretagogues (L-692,429, L-692,585, MK-0677) were discovered using GHRP-6 as a template. Some cyclic peptides as well as penta-, tetra-, and pseudotripeptides have also been described. This review summarizes recent developments in our understanding of the GHRPs,…

  6. 37.

    Argente J, García-Segura LM, Pozo J, Chowen JA · Hormone research · 1996 · PMID 8950613

    Growth hormone (GH)-releasing peptides (GHRPs), a family of synthetic oligopeptides which stimulate GH release, were identified more than a decade ago. The effects of these peptides on GH release have been described in vivo and in vitro, in both animals and humans, using various doses and administration routes. It is generally accepted that GHRPs stimulate the release of GH by acting at the level of the pituitary through a receptor different to that for the endogenous GH-releasing hormone (GHRH)…

  7. 38.

    Vodnik M, Štrukelj B, Lunder M · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2016 · PMID 26551992

    In the recent decades, great progress has been made in the development of ghrelin receptor ligands. The discovery of the first in vitro only active peptide growth hormone secretagogue derived from Met-enkephalin was the foundation for later discoveries of the receptor and the endogenous ligand ghrelin. Since then, the scope of peptides, peptidomimetics, and small-molecules targeting the ghrelin receptor, GHS-R1a, has expanded dramatically. Numerous agonists have been tested in animals and severa…

  8. 39.

    Ghigo E, Arvat E, Camanni F · Annals of medicine · 1998 · PMID 9667794

    Growth hormone secretagogues (GHS) are synthetic, non-natural peptidyl and nonpeptidyl molecules with potent stimulatory effect on somatotrope secretion. They have no structural homology with growth hormone-releasing hormone (GHRH) and act via a specific receptor, which has now been cloned and is present at both the pituitary and hypothalamic level. This evidence strongly suggests the existence of a still unknown natural GHS-like ligand. Several data favour the hypothesis that GHS could countera…

  9. 40.

    Chen C · Clinical and experimental pharmacology & physiology · 2000 · PMID 10831231

    1. Growth hormone (GH) secretion is thought to occur under the reciprocal regulation of two hypothalamic hormones, namely GH-releasing hormone (GHRH) and somatostatin (SRIF), through their engagement with specific cell-surface receptors on the anterior pituitary somatotropes. 2. In addition to GHRH and SRIF, synthetic GH-releasing peptides (GHRP) or GH secretagogue(s) (GHS) regulate GH release through the activation of a novel receptor, the GHS receptor (GHS-R). 3. The cloning of the GHS-R from…

  10. 41.

    Muccioli G, Broglio F, Valetto MR, Ghè C, et al. · Annales d'endocrinologie · 2000 · PMID 10790589

    Growth Hormone (GH)-releasing peptides (GHRPs) and their non peptidyl analogues are synthetic molecules which exhibit strong, dosedependent and reproducible GH-releasing activity but also significant PRL- and ACTH/cortisol-releasing effects. An influence of these compounds on food intake and sleep pattern has been also shown. The neuroendocrine activities of GHRPs are mediated by specific receptors subtypes that have been identified in the pituitary gland, hypothalamus and various extra-hypothal…

  11. 42.

    Veldhuis JD, Bowers CY · Endocrine · 2003 · PMID 14610296

    Technical, genetic, and clinical developments have unveiled a burgeoning array of novel effectors of GH secretion. The present appraisal of central neuroregulatory components of the somatotropic axis highlights a simplifying concept of ensemble control by the final common peptides, GH-releasing hormone (GHRH), GH-releasing peptide(s) (GHRP, ghrelin), and somatostatin. These potent signals act individually, antagonistically, and synergistically to direct pulsatile GH secretion. GHRH, GHRP/ghrelin…

  12. 43.

    Karydis I, Tolis A, Tolis G · Journal of pediatric endocrinology & metabolism : JPEM · 1998 · PMID 10091157

    Thalassemic patients today undergo intensive transfusion and chelation regimes that offer them prolonged survival and improved quality of life. Nevertheless, they face the consequences of chronic illness and therapies which affect multiple bodily functions. Endocrine derangements involve, among others, the GH-IGF-I axis with consequent impairment of growth. In such cases, GH release, as assessed with stimulation tests, may be normal whereas ultradian GH secretion seems to be subnormal. New GH se…

  13. 44.

    Veldhuis JD, Evans WS, Bowers CY, Anderson S · Endocrine · 2001 · PMID 11322501

    Estrogen is the proximate sex steroid sustaining GH secretion throughout the human life span in both sexes. However, very little is known about the specific neuroendocrine mechanisms by which estrogen activates and maintains GH secretion in the young or aging human. The identification of somatostatin in 1973 as a key negative peptidyl regulator of the GH axis and the discovery of GH-releasing hormone (GHRH) in 1982 as a dominant feedforward agonist of GH secretion provided an initial basic scien…

  14. 45.

    Kohler M, Thomas A, Geyer H, Petrou M, et al. · Drug testing and analysis · 2010 · PMID 21204286

    Doping control laboratories are frequently confronted with new substances that may be misused by athletes. Besides new pharmaceuticals, where method development for their detection is dependent on the availability of the substance and corresponding administration studies, some professional and amateur athletes are using illicit 'black market' products, which either differ from known pharmaceuticals but cause similar effects or still are undergoing clinical trials and are therefore rarely availab…

Research Articles

102
  1. 46.

    Doi N, Hirotani C, Ukai K, Shimada O, et al. · Arzneimittel-Forschung · 2004 · PMID 15646370

    KP-102 (D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide dihydrochloride, growth hormone-releasing peptide-2, GHRP-2, pralmorelin, CAS 158861-67-7), is a potent synthetic growth hormone (GH) secretagogue. In the present study, the pharmacological characteristics of the GH-releasing property of KP-102 were investigated by means of in vivo and in vitro experiments. In conscious rats, the GH-releasing activity of KP-102 was more potent than that of exogenously inje…

  2. 47.

    Hirotani C, Oki Y, Ukai K, Okuno T, et al. · Naunyn-Schmiedeberg's archives of pharmacology · 2005 · PMID 15645295

    KP-102 (GHRP-2: pralmorelin) is a synthetic growth hormone releasing peptide (GHRP) that powerfully stimulates the release of GH by acting (i.v.) at both hypothalamic and pituitary sites. Intravenous (i.v.) administration of KP-102 also elicits slight but significant release of adrenocorticotropic hormone (ACTH) in both animals and humans, as is seen with other GHRPs. GHRPs are thought to stimulate the hypothalamic-pituitary-adrenal axis by releasing endogenous ACTH secretagogues such as arginin…

  3. 48.

    Furuta S, Shimada O, Doi N, Ukai K, et al. · Arzneimittel-Forschung · 2004 · PMID 15646371

    The general pharmacological effects of the hexapeptide KP-102 (D-alanyl-3-(2-naphthyl)-D-alanyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide dihydrochloride, growth hormone-releasing peptide-2, GHRP-2, pralmorelin, CAS 158861-67-7), which potently promotes growth hormone (GH) release by acting at both hypothalamic and pituitary sites, were evaluated in various animal experimental models. The administration of KP-102 showed no obvious effect at a pharmacological dose on the central nervous s…

  4. 49.

    Wu D, Chen C, Katoh K, Zhang J, et al. · The Journal of endocrinology · 1994 · PMID 8169551

    A newly synthesised GH-releasing peptide, KP 102 (also named GHRP-2), was studied in an in vitro perifusion system of primary cultured ovine anterior pituitary cells. Application of KP 102 to the perifusion medium caused a dose-dependent increase in GH secretion. Dose-response relationships indicated that KP 102 had similar potency to GRF and was 10-fold more potent than earlier generations of GH-releasing peptide (GHRP-6 and GHRP-1) tested in same system. The response to a second application of…

  5. 50.

    Okano M, Sato M, Ikekita A, Kageyama S · Rapid communications in mass spectrometry : RCM · 2010 · PMID 20552695

    GHRP-2 (pralmorelin, D-Ala-D-(beta-naphthyl)-Ala-Ala-Trp-D-Phe-Lys-NH(2)), which belongs to a class of growth hormone secretagogue (GHS), is intravenously used to diagnose growth hormone (GH) deficiency. Because it may be misused in expectation of a growth-promoting effect by athletes, the illicit use of GHS by athletes has been prohibited by the World Anti-Doping Agency (WADA). Therefore, the mass spectrometric identification of urinary GHRP-2 and its metabolite D-Ala-D-(beta-naphthyl)-Ala-Ala-…

  6. 51.

    Laferrère B, Abraham C, Russell CD, Bowers CY · The Journal of clinical endocrinology and metabolism · 2005 · PMID 15699539

    GHRP-2 is a synthetic agonist of ghrelin, the newly-discovered gut peptide which binds to the growth hormone (GH) secretagogue receptor. Ghrelin has two major effects, stimulating both GH secretion and appetite/meal initiation. GHRP-2 has been extensively studied for its utility as a growth hormone secretagogue (GHS). Animal studies have shown its effect on food intake. However, whether GHRP-2 can also stimulate appetite in humans when administered acutely is not known. We subcutaneously infused…

  7. 52.

    Chen C, Farnworth P, Petersenn S, Musgrave I, et al. · Endocrine · 1998 · PMID 9798733

    Effect of growth hormone-releasing peptide-2 (GHRP-2) on ovine somatotrophs is abolished by a growth hormone-releasing factor (GRF) receptor antagonist, which raises the possibility that GHRP-2 may act on GRF receptors. In the present study, we used rat pituitary GC cells with or without stable transfection of cDNA coding for the human GRF receptor (GC/R+ or GC/R-) to determine whether or not GHRP-2 acts via the GRF receptor. Northern blot analysis indicated that GRF receptor mRNA was undetectab…

  8. 53.

    Semenistaya E, Zvereva I, Thomas A, Thevis M, et al. · Drug testing and analysis · 2015 · PMID 25869809

    Growth hormone releasing peptides (GHRPs) stimulate secretion of endogenous growth hormone and are listed on the World Anti-Doping Agency (WADA) Prohibited List. To develop an effective method for GHRPs anti-doping control we have investigated metabolites of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin in urine after nasal administration. Each compound was administrated to one volunteer. Samples were collected for 2 days after administration, processed by solid-phase extraction on weak cati…

  9. 54.

    Nasu R, Kumagai Y, Kogetsu H, Tsujimoto M, et al. · Drug metabolism and disposition: the biological fate of chemicals · 2005 · PMID 16033952

    Pralmorelin hydrochloride (pralmorelin), consisting of six amino acid residues, is a growth hormone-releasing peptide. The aim of this study is to analyze the pharmacokinetics of pralmorelin after intravenous bolus administration to rats, and to develop a physiologically based pharmacokinetic (PB-PK) model to describe and predict the concentrations of pralmorelin in blood and tissues. Pralmorelin (3 mg/kg) was administered intravenously to 24 Sprague-Dawley rats. Groups of three rats were sacrif…

  10. 55.

    Cox HD, Hughes CM, Eichner D · Drug testing and analysis · 2015 · PMID 25809000

  11. 56.

    Shepherd BS, Eckert SM, Parhar IS, Vijayan MM, et al. · The Journal of endocrinology · 2000 · PMID 11115782

    Abstract Studies in mammals have shown that synthetic Met-enkephalin derivatives, called growth hormone-releasing peptides (GHRPs), stimulate growth hormone (GH) release. The present study was conducted to determine whether the GHRP, KP-102, specifically stimulates GH release in a teleost. Tilapia (Oreochromis mossambicus) were given a single intraperitoneal injection of KP-102 (D-Ala-D-beta;-Nal-Ala-Trp-D-Phe-Lys-NH(2)) or bovine GHRH(1-29)-amide or vehicle and blood was sampled at 1, 6 and 12…

  12. 57.

    Krug O, Thomas A, Malerød-Fjeld H, Dehnes Y, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2018 · PMID 29864719

    Detecting agents allegedly or evidently promoting growth such as human growth hormone (GH) or growth hormone releasing peptides (GHRP) in doping controls has represented a pressing issue for sports drug testing laboratories. While GH is a recombinant protein with a molecular weight of 22 kDa, the GHRPs are short (3-6 amino acids long) peptides with GH releasing properties. The endogenously produced GH (22 kDa isoform) consists of 191 amino acids and has a monoisotopic molecular mass of 22,124 Da…

  13. 58.

    Roh SG, Chen C, Choi KC, Shrestha Y, et al. · Endocrinology · 2002 · PMID 11956179

    It is still controversial in rat whether the stimulation of GH secretion by GH-releasing peptides (GHRP) requires both GHRP receptor (GHRP-R) and GH-releasing hormone receptor (GHRH-R). To clarify this issue, we have postulated that inhibition of GHS-R or GHRH-R gene transcription should block GHRP-2-induced GH secretion. Rat pituitary cells were incubated for 3 days in the presence or absence of antisense 18-mer phosphorothiate oligonucleotides (ONs) complementary to the codon region of GHS-R o…

  14. 59.

    Popławska M, Błażewicz A · Drug testing and analysis · 2019 · PMID 30051972

    Growth hormone releasing peptides (GHRPs) are synthetic peptides with the ability to stimulate human growth hormone (hGH) secretion. Several GHRPs have been developed as drug candidates; however, only one of them, GHRP-2 (Pralmorelin), has received a clinical approval. Nevertheless, they are distributed on the black market and misused by cheating athletes, due to their performance-enhancing effects. Hence, GHRPs have been included in the World-Anti-Doping-Agency's Prohibited List as forbidden su…

  15. 60.

    Gajda PM, Holm NB, Hoej LJ, Rasmussen BS, et al. · Drug testing and analysis · 2019 · PMID 30136411

    A number of unknown pharmaceutical preparations seized by Danish customs authorities were submitted for liquid chromatography-high resolution mass spectrometry (LC-HRMS) analysis. Comparison with reference standards unequivocally identified the content of the powders as analogs of the growth hormone secretagogues GHRP-2 (Pralmorelin), GHRP-6, Ipamorelin, and modified growth hormone releasing factor (modified GRF 1-29), which can be used as performance-enhancing substances in sports. In all cases…

  16. 61.

    Wu D, Chen C, Zhang J, Bowers CY, et al. · The Journal of endocrinology · 1996 · PMID 8699133

    The mechanism of action of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on GH release was investigated in ovine and rat pituitary cells in vitro. In partially purified sheep somatotrophs, GHRP-2 and GH-releasing factor (GRF) increased intracellular cyclic AMP (cAMP) concentrations and caused GH release in a dose-dependent manner; GHRP-6 did not increase cAMP levels. An additive effect of maximal doses of GRF and GHRP-2 was observed in both cAMP and GH levels whereas combined GHRP-6 and GHRP-2 at m…

  17. 62.

    Chen C, Pullar M, Loneragan K, Zhang J, et al. · Journal of neuroendocrinology · 1998 · PMID 9688350

    There is a difference between the sheep and rat somatotrophs in the response to growth hormone-releasing peptide-2 (GHRP-2), which raises the question of what the response may be in human somatotrophs. In the present study, cells were obtained from seven human acromegalic tumours and the effects of GHRP-2 were studied. Cells were dissociated and kept in primary culture for 1-3 weeks before experimentation. Application of GHRP-2 for 30 min induced a significant increase in GH secretion from the c…

  18. 63.

    Furuta S, Hori T, Ohyama T · Naunyn-Schmiedeberg's archives of pharmacology · 2006 · PMID 16773386

    KP-102, a synthetic growth hormone (GH)-releasing peptide, exerts a variety of effects on cardiac function. In the present study, we investigated the direct cardiac effects of KP-102 with regard to ischemia/reperfusion injury by using isolated rat hearts. Isolated Wistar rat hearts were mounted on a Langendorff apparatus and subjected to 30 min of ischemia followed by 40 min of reperfusion. The rat hearts were treated with 0.1-10 nmol/l KP-102 beginning from 15 min before ischemia until the end…

  19. 64.

    Granado M, Priego T, Martín AI, Villanúa MA, et al. · American journal of physiology. Endocrinology and metabolism · 2005 · PMID 15507538

    Chronic arthritis induces hypermetabolism and cachexia. Ghrelin is a gastrointestinal hormone that has been proposed as a treatment to prevent cachexia. The aim of this work was to examine the effect of administration of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) to arthritic rats. Male Wistar rats were injected with Freund's adjuvant, and 15 days later arthritic and control rats were daily injected with GHRP-2 (100 microg/kg) or with saline for 8 days. Arthritis induced an…

  20. 65.

    Chen C, Clarke IJ · Journal of neuroendocrinology · 1995 · PMID 7606243

    The newly synthesized GH-releasing peptide, GHRP-2 (D-Ala-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2), was studied in somatotroph-enriched populations of ovine pituitary cells in primary culture. Nystatin-perforated whole-cell recordings were made on identified somatotrophs after 4-14 days of culture. Using a standard bath solution (containing Na+, Ca2+) and an electrode solution containing K+ in current-clamp recordings, GHRP-2 (10 nM) depolarized the membrane potential of the cells triggering a burst of…

  21. 66.

    Phung LT, Sasaki A, Lee HG, Vega RA, et al. · Domestic animal endocrinology · 2001 · PMID 11164330

    The experiments were conducted to determine the effects of the administration of growth hormone-releasing peptide-2 (GHRP-2, also named KP102), both orally by gavage and in feed, on the release of growth hormone (GH) in swine and to investigate whether attenuation of the GH response occurs after short-term treatment with the peptide in feed. In the first experiment, saline or GHRP-2 at doses of 1, 4.5 and 9 mg/kg body weight (BW) was dissolved in 15 ml saline and administered orally as a bolus b…

  22. 67.

    Kinoshita Y, Tominaga A, Usui S, Arita K, et al. · Endocrine journal · 2013 · PMID 23079545

    The arginine + GHRH test has been established as an alternative to the insulin tolerance test (ITT) for the diagnosis of adult GH deficiency (AGHD). However, the glucagon, arginine, and GH releasing peptide-2 (GHRP-2) test are recommended as alternatives in Japan. The objective of this study was to evaluate the arginine and GHRP-2 tests as alternatives to the ITT for the diagnosis of AGHD in a Japanese population. Three stimulation tests (ITT, arginine test, and GHRP-2 test) were conducted in 71…

  23. 68.

    Arvat E, di Vito L, Maccagno B, Broglio F, et al. · Peptides · 1997 · PMID 9285939

    GHRP-2 (D-Ala-D-beta Nal-Trp-D-Phe-Lys-NH2) and Hexarelin (HEX) (His-D-2-methylTrp-Ala-Trp-DPhe-Lys-NH2) are synthetic, non-natural super-analogs of GHRP-6 endowed with potent stimulatory effect on GH secretion and slight stimulatory effect on PRL, ACTH and cortisol levels. Their GH-releasing activity ahs never been compared each other and their effects on PRL, ACTH and cortisol have never been compared with that of other stimuli. To clarify these points, in 6 normal young adults (22-27 yr) we s…

  24. 69.

    Bowers CY · The Journal of pediatric endocrinology · 1993 · PMID 8374685

    A new class of small synthetic peptides has been developed which specifically release GH. They consist of 6-7 amino acids and release GH in animals as well as humans. So far 3 of these peptides have been administered to humans, i.e., GHRP-6, GHRP-1 and GHRP-2. As in rats, these 3 peptides have been found to be increasingly more effective in releasing GH in humans. All 3 GHRPs release GH more efficaciously than GHRH 1-44 NH2 in humans. Particularly note-worthy is that GHRP-6, GHRP-1 AND GHRP-2 al…

  25. 70.

    Seki Y, Ichihara A · PloS one · 2022 · PMID 35452483

    Growth hormone (GH) deficiency (GHD) is often complicated by non-functioning pituitary tumors (NFPTs); however, its prevalence remains unclear because preoperative screening for GHD with provocative tests is not recommended. Accordingly, we attempted to clarify the characteristics of GHD in unoperated patients with NFPT. We retrospectively reviewed adult patients with non-functioning pituitary adenoma (NFPA) and Rathke's cyst who underwent preoperative GH-releasing peptide-2 (GHRP-2) tests from…

  26. 71.

    Cheng J, Wu TJ, Butler B, Cheng K · Life sciences · 1997 · PMID 9096259

    In the present study, the effect of GHRP-2 on GH release was evaluated in rat primary pituitary cells, and the results were compared with those elicited by GHRP-6. In the rat system, GHRP-2, like GHRP-6, acts synergistically with GRF to release GH. Co-administration of GHRP-2 and GHRP-6 at maximal concentrations had no further effect on GH release than either one alone. The GHRP's were able to desensitize cells to each other, but not to GRF. The effect of GHRP-2 was inhibited by Peptide Antagoni…

  27. 72.

    Thomas A, Kohler M, Mester J, Geyer H, et al. · Drug testing and analysis · 2010 · PMID 20878896

    Black market products of a pharmaceutical nature and nutritional supplements have received substantial and increasing attention because of potential performance enhancement in elite and non-professional sports. In addition, improved general health is claimed for non-competing individuals. The risks and foreseeable dangers of the uncontrolled use of highly potent and non-approved pharmaceutical compounds in healthy individuals are of considerable concern. In the present case report, the emerging…

  28. 73.

    Thomas A, Delahaut P, Krug O, Schänzer W, et al. · Analytical chemistry · 2012 · PMID 23101768

    New, potentially performance enhancing compounds have frequently been introduced to licit and illicit markets and rapidly distributed via worldwide operating Internet platforms. Developing fast analytical strategies to follow these new trends is one the most challenging issues for modern doping control analysis. Even if reference compounds for the active drugs are readily obtained, their unknown metabolism complicates effective testing strategies. Recently, a new class of small C-terminally amid…

  29. 74.

    Zeng P, Li S, Zheng YH, Liu FY, et al. · Peptides · 2014 · PMID 24607724

    GHRP-2 is a synthetic agonist of ghrelin receptor. GHRP-2 has similar physiological functions with ghrelin. In our previous study, ghrelin (i.c.v.) could induce analgesic effect through an interaction with GHS-R1α and with the central opioid system in the acute pain in mice. To date, the function of GHRP-2 in pain processing was not understood. Therefore the aim of this study was to investigate the effects of GHRP-2 on pain modulation at supraspinal level in mice using the tail immersion test. I…

  30. 75.

    Yamamoto D, Ikeshita N, Matsubara T, Tasaki H, et al. · Life sciences · 2008 · PMID 18191156

    Recent reports suggest that Atrogin-1 and MuRF1, E3 ubiquitin ligases, play a pivotal role in muscle atrophy. In the present study, effect of Growth Hormone Releasing Peptide-2 (GHRP-2), a GH secretagogue receptor (GHS-R) agonist, on the expressions of Atrogin-1 and MuRF1 in vivo rat muscles was examined. Dexamethasone administration increased Atrogin-1 mRNA level in rat soleus muscle. The increased mRNA level of Atrogin-1 was significantly attenuated by GHRP-2. In addition, GHRP-2 decreased MuR…

  31. 76.

    Kageyama K, Kushibiki M, Hanada K, Sakihara S, et al. · Regulatory peptides · 2009 · PMID 19682503

    Growth hormone (GH)-releasing peptides (GHRPs) are synthetic peptides which induce strong GH release in both animals and humans. Among them, GHRP-2 is known to stimulate GH release by acting at both hypothalamic and pituitary sites, but also induces adrenocorticotropic hormone (ACTH) release in healthy subjects. GHRP-2 may stimulate ACTH release directly via GHRP receptor type 1a in ACTH-producing tumors. GHRP-2 increases ACTH secretion in rat in vivo, but not ACTH release from rat primary pitui…

  32. 77.

    Ferro P, Krotov G, Zvereva I, Rodchenkov G, et al. · Drug testing and analysis · 2017 · PMID 26811125

    Growth hormone releasing peptides (GHRPs) could be widely used by cheating athletes because they produce growth hormone (GH) secretion, so may generate an ergogenic effect in the body. Knowledge of the essential amino acids needed in GHRP structure for interaction with the target biological receptor GHSR1a, the absorption through different administration routes, and the maintenance of pharmacological activity of potential biotransformation products may help in the fight against their abuse in sp…

  33. 78.

    Raun K, Hansen BS, Johansen NL, Thøgersen H, et al. · European journal of endocrinology · 1998 · PMID 9849822

    The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. As an outcome of a major chemistry programme, ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone-releasing peptide (GHRP)-1. In vitro, ipamorelin released GH from primary rat pituitary cells wi…

  34. 79.

    Granado M, Priego T, Martín AI, Villanúa MA, et al. · American journal of physiology. Endocrinology and metabolism · 2005 · PMID 16030067

    Chronic arthritis is a catabolic state associated with an inhibition of the IGF system and a decrease in body weight. Cachexia and muscular wasting is secondary to protein degradation by the ubiquitin-proteasome pathway. The aim of this work was to analyze the effect of adjuvant-induced arthritis on the muscle-specific ubiquitin ligases muscle ring finger 1 (MuRF1) and muscle atrophy F-box (MAFbx) as well as on IGF-I and IGF-binding protein-5 (IGFBP-5) gene expression in the skeletal muscle. We…

  35. 80.

    Okano M, Nishitani Y, Sato M, Ikekita A, et al. · Drug testing and analysis · 2010 · PMID 21249726

    Administration of exogenous 22 kDa recombinant human growth hormone (rhGH) suppresses the non-22 kDa pituitary growth hormone (GH) secretion by negative feedback; then, the elevated 22 kDa GH to non-22 kDa GH ratio (Rec/Pit ratio) can be utilized to detect doping with rhGH (isoform differential immunoassay). The influence of intravenous administration of growth hormone releasing peptide GHRP-2 on the isoform differential immunoassay for detecting rhGH doping has been investigated.In this study,…

  36. 81.

    Hu X, Xu B, Zhou Z · AAPS PharmSciTech · 2015 · PMID 25761386

    The purpose of this study was to investigate an efficient synthetic route to the mono-PEGylated growth hormone releasing peptide-2 (GHRP-2) and its biological activity in vivo. The commercially available key PEGylating reagent, mPEG-NHS ester, was successfully utilized to the synthesis of mono-PEGylated GHRP-2, during which the PEGylation profiles of GHRP-2 were monitored by high-performance liquid chromatography (HPLC). The product was purified by cation exchange chromatography, and its biologi…

  37. 82.

    Asakura Y, Toyota Y, Muroya K, Adachi M · Journal of pediatric endocrinology & metabolism : JPEM · 2010 · PMID 20662346

    The insulin tolerance test (ITT) has been considered the most reliable test in the diagnosis of growth hormone deficiency (GHD), but it is contraindicated in some patients. Recently, the use of GH-Releasing Peptide-2 (GHRP-2) has been validated and reported as a safe and reliable test for the diagnosis of adult severe GHD. We evaluated the GH response to GHRP-2 in 56 children with growth disorders to assess its efficacy. A dose of 2 microg/kg of GHRP-2 was administered intravenously and serum GH…

  38. 83.

    Reverter-Branchat G, Segura J, Pozo OJ · Drug testing and analysis · 2021 · PMID 33197153

    Dried blood spots (DBSs) sampling is gaining support by the antidoping community because of simplicity and cost-effective characteristics, especially in collection, transport, and storage. Nevertheless, DBS applicability demands specific studies for each of the analytes proposed for testing. Here, GHRP-2 has been selected as a representing member of the growth hormone-releasing peptides (GHRPs) family to provide further evidence of DBS suitability for GHRPs abuse detection in sport testing. An a…

  39. 84.

    Phung LT, Inoue H, Nou V, Lee HG, et al. · Domestic animal endocrinology · 2000 · PMID 10793268

    The effects of GHRP-2 (also named KP102), a new growth hormone-releasing peptide, on the release of growth hormone (GH) and growth performance were examined in swine. The single intravenous (i. v.) injection of GHRP-2 at doses of 2, 10, 30 and 100 microg/kg body weight (BW) to cross-bred castrated male swine stimulated GH release in a dose-dependent manner, with a return to the baseline by 120 min. The peak GH concentrations and GH areas under the response curves (GH AUCs) for 180 min after the…

  40. 85.

    Roh SG, Hirota M, He ML, Matsunaga N, et al. · Endocrine journal · 1997 · PMID 9622303

    This study was performed to investigate whether the blockade of cholinergic muscarinic and adrenergic pathways was involved in the GH-releasing effect of GH-releasing peptide-2 (GHRP-2) in ovariectomized ewes. Cholinergic muscarinic antagonist, atropine (0.2 mg/kg, i.v., 15 min before GHRP-2 administration) blunted the GH secretion caused by GHRP-2 (12.5 microg/kgBW). alpha-Adrenergic antagonist phentolamine (15 microg/kgBW x min, infusion from -15 to 30 min) did not affect the GH response to GH…

  41. 86.

    Ohara E, Tokuyama H, Kitamoto T, Kitahara A, et al. · Obesity surgery · 2017 · PMID 28623445

    Because growth hormone (GH) secretion is reportedly decreased in obese patients, we examined not only the factors associated with the decreased GH secretion but also GH response to the GH-releasing peptide (GHRP)-2-load test before and after laparoscopic gastrectomy (LSG). The study comprised 28 individuals aged 19-65 years [mean body mass index (BMI), 39.4 ± 9.4 kg/m

  42. 87.

    Pinyot A, Nikolovski Z, Bosch J, Such-Sanmartín G, et al. · Analytical and bioanalytical chemistry · 2012 · PMID 22083629

    Growth hormone secretagogues (GHS) constitute a new GH deficiency treatment increasing exponentially in number and improved potency and bioavailability over the last decade. The growth hormone releasing activity makes these compounds attractive for the artificial improvement of the human sports skills, now that recombinant human growth hormone (rhGH) administration is effectively detected. The GHS family is extremely diverse both in number and chemical heterogeneity and keeps growing continuousl…

  43. 88.

    Teramoto S, Tahara S, Hattori Y, Kondo A, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2023 · PMID 37295337

    The growth hormone (GH)-releasing peptide-2 (GHRP-2) test is relatively safe among endocrine stimulation tests for the elderly. We investigated whether anterior pituitary function in elderly patients could be assessed on the basis of GH response to the GHRP-2 test. Sixty-five elderly patients aged 65 years and older with non-functioning pituitary neuroendocrine tumor (PitNET) who underwent pituitary surgery and preoperative endocrine stimulation tests were classified into the "GH normal group" a…

  44. 89.

    Kageyama K, Sakihara S, Kameda W, Sugiyama A, et al. · Endocrine journal · 2018 · PMID 29973439

    Thyrotropin (TSH)-producing adenomas are a rare cause of hyperthyroidism and are a type of functional pituitary adenoma. The diagnosis of TSH-producing adenoma is a challenging problem in clinical endocrinology. Since growth hormone-releasing peptide-2 (GHRP-2) fails to induce TSH secretion in normal subjects, the effect of GHRP-2 on TSH levels was therefore examined in patients with TSH-producing adenomas. A total of 5 patients (4 women and 1 man) referred to our departments for further evaluat…

  45. 90.

    Thomas A, Höppner S, Geyer H, Schänzer W, et al. · Analytical and bioanalytical chemistry · 2011 · PMID 21298258

    A family of small peptides has reached the focus of doping controls representing a comparably new strategy for cheating sportsmen. These growth hormone releasing peptides (GHRP) are orally active and induce an increased production of endogenous growth hormone (GH). While the established test for exogenous GH fails, the misuse of these prohibited substances remains unrecognized. The present study provides data for the efficient extraction of a variety of known drug candidates (GHRP-1, GHRP-2, GHR…

  46. 91.

    Granado M, Martín AI, López-Menduiña M, López-Calderón A, et al. · American journal of physiology. Endocrinology and metabolism · 2008 · PMID 17986630

    It has been reported that growth hormone (GH)-releasing peptide-2 (GHRP-2), a ghrelin receptor agonist, has an anti-inflammatory effect. We investigated whether this GH secretagogue attenuates liver injury in LPS-treated rats. Wistar rats were simultaneously injected (ip) with LPS (1 mg/kg) and/or GHRP-2 (100 microg/kg). Serum levels of aspartate and alanine transaminases were measured as an index of liver damage. Circulating nitrites/nitrates and hepatic IGF-I and TNF-alpha were evaluated as po…

  47. 92.

    Yan M, Hernandez M, Xu R, Chen C · European journal of endocrinology · 2004 · PMID 14763922

    Growth hormone (GH)-releasing hormone (GHRH) and GH-releasing peptides (GHRPs) stimulate the release of GH through their specific receptors on somatotropes. Combined GHRH and GHRP administration causes a synergistic GH release in vivo by an unknown mechanism. The current study focuses on the direct action of GHRH and GHRP on several molecular targets in somatotropes. To clarify the mechanism of action, ovine somatotropes were used to measure the expression of mRNAs encoding for GH, pituitary tra…

  48. 93.

    Fintini D, Alba M, Schally AV, Bowers CY, et al. · Neuroendocrinology · 2005 · PMID 16601359

    GH secretagogues (GHS) are synthetic ghrelin receptor agonists that stimulate GH secretion. It is not clear whether they act predominantly by stimulating the secretion of hypothalamic growth hormone-releasing hormone (GHRH), or directly on the somatotrope cells. In addition, it is not known whether combined treatment with GHRH and GHS has synergistic effects on growth. To address these questions, we used the GH-deficient GHRH knock out (GHRHKO) mouse model, which has severe somatotrope cell hypo…

  49. 94.

    Chen C · Endocrinology · 2002 · PMID 12072399

    Long-term in vivo treatment with synthetic GH-releasing peptides (GHRPs) enhances the release of GH induced by endogenous GHRH. The mechanism for such an enhancement on GH release is unknown. In this experiment, somatotropes were obtained from ovine pituitaries by enzyme dissociation and enriched by density centrifugation. Membrane voltage and currents were recorded with whole-cell patch-clamp configuration. After 48-h treatment with GHRP-2 (10(-8) M), the percentage of cells with spontaneous ac…

  50. 95.

    Soga A, Fukuda I, Kobayashi S, Tahara S, et al. · Endocrine journal · 2020 · PMID 31776295

    Non-functioning pituitary adenoma (NFPA) is one common cause of adult growth hormone deficiency (AGHD). In Japan, a GH-releasing peptide (GHRP)-2 test is used to evaluate GH secretion. Although the cut-off for peak GH during a GHRP-2 test for severe AGHD is ≤9 ng/mL, severe AGHD may further diminish responses (range, nearly no-response to ≤9 ng/mL). We studied whether the peak GH responses during a GHRP-2 test could be predicted based on clinical characteristics of patients with NFPA. We compare…

  51. 96.

    Kamoi K, Minagawa S, Kimura K, Ishizawa M, et al. · Endocrine journal · 2010 · PMID 19907099

    Ghrelin has a stimulating effect on arginine vasopressin (AVP). However, it is not known whether GHRP-2, a synthetic ghrelin receptor agonist, also has a stimulating effect on AVP release in men. To determine whether the GHRP-2 test is useful for assessing AVP secretion, blood ACTH, GH, FSH, LH, PRL, TSH and AVP levels, as well as glucose, osmolality, sodium and hematocrit, were measured before and 15, 30, 45 and 60 min after an intravenous bolus of 100 microg GHRP-2 in 10 healthy men with and w…

  52. 97.

    Chao YN, Sun D, Peng YC, Wu YL · International journal of molecular sciences · 2016 · PMID 27548147

    Cyclooxygenase-2 (COX-2) and interleukin-8 (IL-8) are two important inflammatory mediators in ovulation. Ghrelin may modulate inflammatory signaling via growth hormone secretagogue receptors. We investigated the role of ghrelin in KGN human ovarian granulosa cells using protein kinase C (PKC) activator phorbol 12, 13-didecanoate (PDD) and synthetic ghrelin analog growth hormone releasing peptide-2 (GHRP-2). GHRP-2 attenuated PDD-induced expression of protein and mRNA, the promoter activity of CO…

  53. 98.

    Tsukamoto N, Otsuka F, Miyoshi T, Inagaki K, et al. · Molecular and cellular endocrinology · 2011 · PMID 21742013

    Mechanisms by which GHRP stimulates ACTH release in corticotrope cells were investigated using mouse corticotrope AtT20 cells by focusing on the biological activity of BMP-4. GHRP-2 increased ACTH and cAMP secretion by AtT20 cells; however, its effects were less potent than the effects of CRH. BMP-4 suppressed basal ACTH production and POMC transcription, and the inhibition of endogenous BMP receptor signaling led to an increase in ACTH production. Of note, BMP-4 suppressed ACTH production and P…

  54. 99.

    Sawada H, Sugihara H, Onose H, Minami S, et al. · Regulatory peptides · 1994 · PMID 7846295

    The effect of a newly developed growth hormone (GH)-releasing hexapeptide (KP-102) on GH secretion was studied in urethan-anesthetized adult male rats. Although KP-102 alone exerted a small influence on GH secretion, it produced a large plasma GH response in the presence of exogenous GH-releasing factor (GRF). During the continuous infusion of GRF, the somatotropes became refractory to a large bolus dose of GRF, but KP-102 induced a marked increase of plasma GH. The GH response to KP-102 alone o…

  55. 100.

    Gupta D, Chuang JC, Mani BK, Shankar K, et al. · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019 · PMID 30758330

    The ghrelin system is a key component of the mood and metabolic responses to chronic psychosocial stress. For example, circulating acyl-ghrelin rises in several rodent and human stress models, administered acyl-ghrelin induces antidepressant-like behavioral responses in mice, and mice with deleted ghrelin receptors (GHSRs) exhibit exaggerated depressive-like behaviors, changed eating behaviors, and altered metabolism in response to chronic stress. However, the mechanisms mediating stress-induced…

  56. 101.

    Dhali A, Ray S, Dhali GK, Ghosh R, et al. · International journal of surgery case reports · 2021 · PMID 34090190

    GIST and NICTH are mesenchymal in origin however there are very few reports of GIST associated with NICTH which is a para neoplastic syndrome, generally diagnosed when a tumour induced hypoglycaemia is noted. A 46 years old female with prime complain of awareness of a mass in the upper abdomen was admitted for evaluation and further management. Detailed investigation revealed the mass to be gastrointestinal stromal tumour. On the day of admission patient was found to be hypoglycaemic which didn'…

  57. 102.

    Titterington JS, Sukhanov S, Higashi Y, Vaughn C, et al. · Endocrinology · 2009 · PMID 19819949

    GH-releasing peptide-2 (GHRP-2) is a synthetic peptide that increases circulating GH and IGF-I levels. It also binds to CD36, a scavenger receptor for oxidized low-density lipoprotein (OxLDL), and may prevent cellular uptake of this proatherogenic complex. To determine its potential antiatherogenic effects, GHRP-2 (20 microg twice daily) was administered sc to ApoE(-/-) mice for 12 wk. GHRP-2 increased circulating IGF-I 1.2- to 1.6-fold and decreased circulating interferon-gamma by 66%. Although…

  58. 103.

    Kudoh K, Shibata C, Funayama Y, Fukushima K, et al. · Journal of gastroenterology · 2009 · PMID 19271111

    The aim of this study was to evaluate the effect of growth hormone releasing peptide (GHRP)-2, a synthetic ligand for the growth hormone secretagogue receptor, on upper gastrointestinal motility and food intake. Five neurally intact dogs and five dogs with vagotomy and pyloroplasty were equipped with strain gauge force transducers on the stomach, duodenum and jejunum. GHRP-2 (0.5-10 microg/kg) was administered intravenously in neurally intact dogs in the interdigestive state and after feeding. T…

  59. 104.

    Sheriff S, Joshi R, Friend LA, James JH, et al. · Peptides · 2009 · PMID 19577604

    Thermal injury results in hypermetabolism, loss of body weight, and skeletal muscle wasting in mice and rats. Our earlier studies have demonstrated that ghrelin injection stimulates food intake and growth hormone release and inhibits skeletal muscle proteolysis in rats with thermal injury. We sought to develop a lower molecular weight, stable and longer acting peptide to combat the catabolic responses caused by thermal injury. Towards this goal, we examined the role of the hexapeptide mimetic of…

  60. 105.

    Kamegai J, Hasegawa O, Minami S, Sugihara H, et al. · Brain research. Molecular brain research · 1996 · PMID 8804723

    Growth hormone-releasing hexapeptide (GHRP) stimulates GH secretion by acting on both the pituitary and the hypothalamus through a poorly understood mechanism. To reveal the hypothalamic action of GHRP, rat brains were processed for in situ hybridization for c-fos mRNA as a marker of neuronal activity after systemic administration of a newly developed GHRP, KP-102. Hypophysectomized adult male Wistar rats were administered KP-102 through an indwelling right atrial cannula. KP-102 treatment was a…

  61. 106.

    Balasubramaniam A, Joshi R, Friend LA, James JH · Advances in experimental medicine and biology · 2009 · PMID 19400318

  62. 107.

    Lee HG, Choi YJ, Lee SR, Kuwayama H, et al. · Domestic animal endocrinology · 2005 · PMID 15713362

    This study was conduct to determine the influence of dietary protein on the response of plasma insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding proteins (IGFBPs) to exogenous growth hormone releasing peptide-2 (GHRP-2 or KP 102) in Holstein steers. Eight 16-month-old Holstein steers were grouped by liveweight to two feeding treatments; high protein (HP; CP 1.38 kg/day and TDN 4.5 kg/day DM intake, n=4) or low protein (LP; CP 0.66 kg/day and TDN 4.42 kg/day DM intake, n…

  63. 108.

    Drennon K, Moriyama S, Kawauchi H, Small B, et al. · General and comparative endocrinology · 2003 · PMID 12957475

    We report the development of a sensitive, and specific, competitive, antigen-capture enzyme-linked immunosorbent assay for the measurement of channel catfish (Ictalurus punctatus) growth hormone (cfGH). The detection limit of the assay (90% binding) was 2.0ng/ml and the ED(50) value (standard curve range 150-0.59 ng/ml) was 67.3 ng/ml. Recovery of cfGH-spiked plasma samples was determined to be 102%. Dose-response inhibition curves using serially diluted pituitary homogenates and plasma samples…

  64. 109.

    Alba M, Fintini D, Bowers CY, Parlow AF, et al. · American journal of physiology. Endocrinology and metabolism · 2005 · PMID 15985453

    Growth hormone (GH) secretagogues (GHS) stimulate GH secretion in vivo in humans and in animals. They act on the ghrelin receptor, expressed in both the hypothalamus and the pituitary. It is unknown whether GHSs act predominantly by increasing the release of hypothalamic GH-releasing hormone (GHRH) or by acting directly on the somatotroph cells. We studied whether a potent GHS could stimulate growth in the absence of endogenous GHRH. To this end, we used GHRH knockout (GHRH-KO) mice. These anima…

  65. 110.

    Kato Y, Iwase M, Ichihara S, Kanazawa H, et al. · Circulation journal : official journal of the Japanese Circulation Society · 2010 · PMID 19942785

    Growth hormone-releasing peptide (GHRP) may act directly on the myocardium and improve left ventricular (LV) function, suggesting a potential new approach to the treatment of cardiomyopathic hearts. The present study tested the hypothesis that the beneficial cardiac effects of GHRP might include attenuation of myocardial oxidative stress. Dilated cardiomyopathic TO-2 hamsters were injected with GHRP-2 (1 mg/kg) or saline from 6 to 12 weeks of age. F1B hamsters served as controls. Untreated TO-2…

  66. 111.

    Bercu BB, Walker RF · Acta paediatrica (Oslo, Norway : 1992). Supplement · 1997 · PMID 9401554

    A diagnostic test was devised to evaluate pituitary growth hormone (GH) secretory potential. GH secretory dynamics were assessed in children with and without GH deficiency. The GH response was measured to GH-releasing hormone (GHRH) and the GH-releasing peptide GHRP-2, administered sequentially. The mean (+/- SEM) peak GH response to GHRP-2 was 20.1 +/- 5.5, 63.6 +/- 24.9 and 42.2 +/- 4.3 micrograms/l for GH-deficient, slowly growing non-GH-deficient and control children, respectively (p < 0.02…

  67. 112.

    Roh SG, Matsunaga N, Hidaka S, Hidari H · Endocrine journal · 1996 · PMID 8886623

    This study was conducted to determine the effects of acute and chronic administration of GH-releasing peptide-2 (D-Ala-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2, GHRP-2 or KP102) on GH responsiveness in male Holstein calves. In the dose response study of acute administration, six calves were injected iv with saline or 6.25, 12.5 and 25.0 micrograms/kg body weight (BW) of KP102. The GH AUC (area under curve, ng/ml.min, mean +/- SEM) for 60 min was significantly increased with 6.25 (676.3 +/- 125.6), 12.5…

  68. 113.

    Gondo RG, Aguiar-Oliveira MH, Hayashida CY, Toledo SP, et al. · The Journal of clinical endocrinology and metabolism · 2001 · PMID 11443201

    GH-releasing peptides (GHRPs) are synthetic peptides that bind to specific receptors and thereby stimulate the secretion of pituitary GH. In vivo it is uncertain whether these peptides act directly on somatotroph cells or indirectly via release of GHRH from the hypothalamus. In this study we compared the pituitary hormone response to GHRP-2 in 11 individuals with isolated GH deficiency (GHD) due to a homozygous mutation of the GHRH receptor (GHRH-R) gene and in 8 normal unrelated controls. Basal…

  69. 114.

    Tanaka T, Hasegawa Y, Yokoya S, Nishi Y · Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2014 · PMID 25374440

    We investigated whether treatment with an intranasal GH-releasing peptide (GHRP)-2 spray, which acts as a potent GH secretagogue that stimulates endogenous GH secretion, promotes growth in patients with GH deficiency (GHD). This study involved 126 prepubertal short children (81 males, 45 females) with a height SD score of -2 SD or less, who had been diagnosed as having GHD based on GH stimulation tests, and in whom the serum GH concentrations increased up to 9 ng/ml after preliminary administrat…

  70. 115.

    Shibasaki T, Yamauchi N, Takeuchi K, Ishii S, et al. · Neuroscience letters · 1998 · PMID 9839714

    The effects of fasting, restraint stress, and intracerebroventricular (i.c.v.) injection of somatostatin on the growth hormone secretagogue, KP-102-induced stimulation of food intake were examined in rats. KP-102-induced stimulation of food intake was observed in freely-fed rats but not in 24-h starved rats. A 90 min period of restraint stress decreased food intake, and i.c.v. administration of KP-102 counteracted the suppressive effect of restraint on food intake. I.c.v. administration of somat…

  71. 116.

    Soares-Welch C, Farhy L, Mielke KL, Mahmud FH, et al. · The Journal of clinical endocrinology and metabolism · 2005 · PMID 15634714

    The present study examines the thesis that pulsatile GH secretion is controlled simultaneously by three principal signals; viz., GHRH, GH-releasing peptide (GHRP, ghrelin), and somatostatin (SS). According to this ensemble notion, no single regulatory peptide acts alone or can be interpreted in isolation. Therefore, to investigate gender-specific control of pulsatile GH secretion, we designed dual-effector stimulation paradigms in eight young men and six women as follows: 1) L-arginine/GHRH (to…

  72. 117.

    Nemoto T, Sugihara H, Mano A, Kano T, et al. · Peptides · 2011 · PMID 21514337

    Ghrelin, the endogenous ligand for growth hormone secretagogues (GHSs) receptor (GHS-R), increases adrenocorticotropin (ACTH) and cortisol (corticosterone) as well as GH secretion in humans and animals. However, the site of GHSs action to induce ACTH secretion is not fully understood. To clarify the mechanisms of the action of ghrelin/GHSs on ACTH secretion, we analyzed the effects of KP-102 and ghrelin on the mRNA expression and release of corticotropin releasing factor (CRF) and arginine vasop…

  73. 118.

    Weekers F, Michalaki M, Coopmans W, Van Herck E, et al. · Endocrinology · 2004 · PMID 14551231

    Treatment with recombinant human GH (rhGH) increases the mortality of critical illness. We postulated that combined GH-releasing peptide-2 (GHRP-2), TRH, and insulin infusion is a less toxic anabolic strategy through a putative inability to overstimulate the GH axis and a capacity to normalize thyroid hormone concentrations while foregoing excessive hyperglycemia. Burn-injured, parenterally fed, New Zealand White rabbits were randomized to receive 4-d treatment with saline (n=8); 60 microg/kg.h…

  74. 119.

    Thomas A, Görgens C, Guddat S, Thieme D, et al. · Journal of separation science · 2016 · PMID 26578461

    The analysis of low-molecular-mass peptides in doping controls has become a mandatory aspect in sports drug testing and, thus, the number of samples that has to be tested for these analytes has been steadily increasing. Several peptides <2 kDa with performance-enhancing properties are covered by the list of prohibited substances of the World Anti-Doping Agency including Desmopressin, LH-RH, Buserelin, Triptorelin, Leuprolide, GHRP-1, GHRP-2, GHRP-3, GHRP-4, GHRP-5,GHRP-6, Alexamorelin, Ipamoreli…

  75. 120.

    Roh SG, Doconto M, Feng DD, Chen C · Endocrine · 2006 · PMID 17185792

    GH secretion is regulated by GHRH and somatostatin via actions on their specific receptors in pituitary somatotropes. Ghrelin and synthetic analogs, GHRPs, also stimulate GH release via GHS-receptors (GHS-R). To examine the long-term effect of GHRH and/or GHRP on somatotropes, primary cultured ovine somatotropes were treated with GHRH (10(-9) and 10(-8) M) and GHRP-2 (10(-8) and 10(-7) M) for up to 2 d. After treatment, culture medium was collected for GH assay, and total RNA was extracted for R…

  76. 121.

    Nakagawa T, Ukai K, Ohyama T, Koida M, et al. · Life sciences · 1996 · PMID 8761023

    KP-102 (D-Ala-D-beta-Nal-Ala-Trp-D-Phe-Lys-NH2), a new second generation hexapeptide, has a potent growth hormone (GH)-releasing action in vivo and in vitro. Here, we evaluated the GH-releasing action of KP-102 under pentobarbital (PB) anesthesia in neonatally sodium-glutamate-monohydrate-treated low growth (NMSG-LG) rats. The plasma GH level in NMSG-LG rats after i.v. administration of KP-102 at 100 micrograms/kg was 1/6.7 (95% C.L. 1/14.7 - 1/3.0) of that in normal rats given the same dose (p…

  77. 122.

    Taniguchi Y, Yoshikawa T, Yamada T, Kawaguchi H · In vivo (Athens, Greece) · 2026 · PMID 41482410

    Growth hormone (GH) secretion patterns differ across species. Humans exhibit a nocturnal surge, while rodents exhibit ultradian pulses. In cynomolgus monkeys, diurnal and daily variations and responsiveness to exogenous GH-releasing hormone (GHRH) remain insufficiently defined in non-clinical studies. This study aimed to characterize GH secretion patterns and evaluate responsiveness to exogenous GHRH in adult male cynomolgus monkeys for pituitary toxicity studies. Serum from 10 animals was colle…

  78. 123.

    Kondo T, Suga H, Takeuchi K, Fuse Y, et al. · Diseases (Basel, Switzerland) · 2025 · PMID 40277822

    Our objective is to develop hormone-producing pituitary cells that can function in the same manner as the human body and provide more effective treatments than current hormone replacement therapy. We have already established a technique for generating hypothalamic-pituitary organoids using feeder-free human pluripotent stem cells (hPSCs) and demonstrated their effectiveness in vivo through transplantation into hypopituitary mouse models. To prospectively determine the upper limit of transplantin…

  79. 124.

    Perboni S, Bowers C, Kojima S, Asakawa A, et al. · World journal of gastroenterology · 2008 · PMID 19009643

    The cancer-associated anorexia-cachexia syndrome is observed in 80% of patients with advanced-stage cancer, and is one of the major obstacles in chemotherapy. Ghrelin is a orexigenic hormone that has been proposed to prevent anorexia. Aim of the study was to determine whether the addition of the ghrelin agonist growth hormone releasing peptide 2 (GHRP-2) to cytotoxic therapy with 5-fluoruracil (5-FU) prevents the anorexia associated with chemotherapy in cancer cachectic mice. Thirty-three BALB/c…

  80. 125.

    Li Y, Yao L, Zhang C, Li T, et al. · Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association · 2025 · PMID 39672241

    To explore the potential of growth hormone-releasing peptide 2 (GHRP-2) for tendon-bone healing in a rat rotator cuff tear (RCT) model. The impact of GHRP-2 on M1 macrophage polarization in vitro was determined using real-time polymerase chain reaction, Western blot, and immunofluorescence staining. GHRP-2 was then applied in a rat RCT model, and the healing of the tendon-bone interface was systemically evaluated by histologic staining, radiologic assessments, gait analysis, and biomechanical te…

  81. 126.

    Xu R, Zhao Y, Chen C · The Journal of physiology · 2002 · PMID 12456822

    Inward-rectifying potassium (Kir) channels are essential for maintaining the resting membrane potential near the K(+) equilibrium and they are responsible for hyperpolarisation-induced K(+) influx. We characterised the Kir current in primary cultured ovine somatotropes and examined the effect of growth hormone-releasing peptide-2 (GHRP-2) on this current and its related intracellular signalling pathways. The Kir current was, in most cases, isolated using nystatin-perforated patch-clamp technique…

  82. 127.

    Sigalos JT, Pastuszak AW, Allison A, Ohlander SJ, et al. · American journal of men's health · 2017 · PMID 28830317

    Realizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endogenous GH is needed. Several GH secretagogues are available, including GH-releasing peptides (GHRPs) GHRP-2 and GHRP-6, and the GH-releasing hormone analog, sermorelin (SERM). Insulin-like growth factor 1 (IGF-1) serves as a surrogate marker for GH. Here, the effect of GHRP/SERM therapy on IGF-1 levels is evaluated. A retrospective review of medical records was performed f…

  83. 128.

    Tschöp M, Statnick MA, Suter TM, Heiman ML · Endocrinology · 2002 · PMID 11796511

    Ghrelin, an endogenous GH secretagogue, is capable of stimulating adiposity in rodents. Because such adiposity was thought to be mediated by hypothalamic NPY neurons, we investigated by which mechanism a synthetic ghrelin receptor agonist, GHRP-2, would generate a positive energy balance in NPY-deficient [Npy(-/-) mice] and wild-type controls. A dose-dependent increase in body weight and food intake was observed during daily sc injections with GHRP-2. Pre- and posttreatment analysis of body comp…

  84. 129.

    Haruta I, Fuku Y, Kinoshita K, Yoneda K, et al. · Journal of cachexia, sarcopenia and muscle · 2015 · PMID 26401470

    In Japan, growth hormone releasing peptide-2 (GHRP-2) is clinically used as a diagnostic agent for growth hormone secretion deficiency, but the therapeutic application of GHRP-2 has not been studied in anorexia nervosa. GHRP-2 reportedly exhibits agonistic action for ghrelin receptor and increases food intake. We administered GHRP-2 to a patient with a 20-year history of anorexia nervosa to determine whether GHRP-2 treatment increases food intake and body weight. GHRP-2 was administered before e…

  85. 130.

    Timms M, Hall N, Levina V, Vine J, et al. · Drug testing and analysis · 2014 · PMID 24574167

    The growth hormone releasing peptides (GHRPs) hexarelin, ipamorelin, alexamorelin, GHRP-1, GHRP-2, GHRP-4, GHRP-5, and GHRP-6 are all synthetic met-enkephalin analogues that include unnatural D-amino acids. They were designed specifically for their ability to stimulate growth hormone release and may serve as performance enhancing drugs. To regulate the use of these peptides within the horse racing industry and by human athletes, a method is presented for the extraction, derivatization, and detec…

  86. 131.

    Wu D, Clarke IJ, Chen C · The Journal of endocrinology · 1997 · PMID 9291832

    The involvement of protein kinase C (PKC) in the action of GH-releasing factor (GRF) and synthetic GH-releasing peptides (GHRP-2 and GHRP-6) was investigated in ovine somatotrophs in primary culture. In partially purified sheep somatotrophs, GRF and GHRP-2 caused translocation of PKC activity from the cytosol to the cell membranes and caused GH release in a dose- and time-dependent manner. GHRP-6 did not cause PKC translocation. The PKC inhibitors, calphostin C, staurosporine and chelerythrine,…

  87. 132.

    Johansen PB, Hansen KT, Andersen JV, Johansen NL · Xenobiotica; the fate of foreign compounds in biological systems · 1998 · PMID 9879640

    1. The pharmacokinetics of three new peptidyl growth hormone secretagogues, ipamorelin (NNC 26-0161), NNC 26-0194 and NNC 26-0235, were compared with two well-known hexapeptides, GHRP-2 and GHRP-6, in the male rat following different routes of administration. 2. Following i.v. bolus injection, plasma concentrations of the peptides declined biexponentially. Ipamorelin differed markedly from the other peptides investigated, demonstrating a systemic plasma clearance 5-fold lower than that of GHRP-6…

  88. 133.

    Liu Q, Bai X, Liu K, Lin W, et al. · Journal of Tongji Medical University = Tong ji yi ke da xue xue bao · 1999 · PMID 12938517

    Growth hormone releasing peptide (GHRP-2) is a synthetic hexapeptide which specifically stimulates secretion of growth hormone (GH) by fetal pituitary somatotrophs through a new membrane receptor, which is different from growth hormone releasing hormone (GHRH) and somatostatin (SMS) receptors. We used cell cultures of human fetal pituitary somatotroph cells to investigate the effect of GHRH, GHRP-2 and somatostatin on GH secretion. The results showed that the mechanism of GHRH/SMS and GHRP-2 was…

  89. 134.

    Adams EF, Lei T, Buchfelder M, Bowers CY, et al. · Molecular endocrinology (Baltimore, Md.) · 1996 · PMID 8721987

    The effects of the synthetic GH-releasing peptides, GHRP-2 and GHRP-6, on phosphatidylinositol (PI) hydrolysis and cAMP production have been examined in human pituitary somatotropinomas with and without adenylyl cyclase-activating gsp oncogenes. Both peptides dose-dependently stimulated the rate of PI hydrolysis and GH secretion by cell cultures of both types of somatotropinoma. GHRP-2 was considerably more potent than GHRP-6. The effects on GH secretion were reduced or abolished by phloretin, a…

  90. 135.

    Roh SG, He ML, Matsunaga N, Hidaka S, et al. · Journal of animal science · 1997 · PMID 9331880

    We investigated the desensitization caused by growth hormone (GH)-releasing peptide-2 (D-Ala-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2; GHRP-2) in vivo using calves. The GHRP-2 (12.5 micrograms.kgBW-1.h-1) or GH-releasing factor (GRF; .125 microgram.kgBW-1.h-1) were infused for 180 min into four calves, each followed by either GHRP-2 (12.5 micrograms/kg BW) or GRF (.125 microgram/kg BW) injection after 60 min. All treatments were given to all of the calves. The continuous infusion of GHRP-2 did not atten…

  91. 136.

    Chen C, Roh SG, Nie GY, Loneragan K, et al. · Endocrine · 2001 · PMID 11322504

    Although existing data suggest an influence of leptin on circulating levels of growth hormone (GH), the action site and properties of leptin are still controversial. Using primary cultured ovine pituitary cells, we studied the direct effect of leptin on the secretion of GH. Pituitary cells were dissociated by collagenase and subjected to Percoll gradient centrifugation to enrich the somatotroph population to 60-80% of cells. Treatment of primary cultured ovine somatotrophs with leptin (10(-9)-10…

  92. 137.

    Li G, Li J, Zhou Q, Song X, et al. · The Tohoku journal of experimental medicine · 2010 · PMID 20805679

    Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are the most common complications of sepsis, and the mortality of sepsis-induced ALI remains high in critically ill patients. Growth hormone releasing peptide-2 (GHRP-2), a ghrelin agonist, has been shown to exert beneficial effects on various inflammatory diseases. We therefore explored whether GHRP-2 possesses anti-inflammatory properties in the pathogenesis of lipopolysaccharide (LPS)-induced ALI. Male Sp…

  93. 138.

    Shepherd BS, Johnson JK, Silverstein JT, Parhar IS, et al. · Comparative biochemistry and physiology. Part A, Molecular & integrative physiology · 2007 · PMID 17240179

    The effects of growth hormone secretagogues (GHSs) on the teleost somatotropic axis are poorly understood, particularly with respect to insulin-like growth factor-I (IGF-I) and the IGF-binding proteins (IGFBPs). To assess the endocrine and orexigenic responses of rainbow trout (Oncorhynchus mykiss) to GHS treatment, animals were injected with human GHRH(1-29)-amide, KP-102 or rat ghrelin at 0, 1 or 10 pmol/g body mass. Feed intake was tested at 2 and 5 h post-injection and plasma levels of growt…

  94. 139.

    Králík F, Kvíčalová A, Salaďáková A, Kuchař M, Setnička V. · 2026 · PMID 41555539

    Growth hormone-releasing peptides (GHRPs) comprise a group of small synthetic peptides that can effectively influence growth hormone secretion both in humans and animals. As many health conditions are associated with growth hormone dysregulation, this class of compounds seems to be good candidates for various therapeutic purposes. However, GHRPs are also associated with doping in professional sports and they have been abused by amateur sportsmen and bodybuilders as well. In the present work, we…

  95. 140.

    Seki Y, Morimoto S, Bokuda K, Watanabe D, Yamashita K, Takano N, Amano K, Kawamata T, Ichihara A. · 2023 · PMID 38024646

    <h4>Context</h4>GH supplementation for GH deficiency (GHD) has been reported to decrease high-sensitivity C-reactive protein (hs-CRP), an inflammatory marker; however, the association between GHD and hs-CRP remains unclear.<h4>Objective</h4>We aimed to clarify the impact of impaired GH secretion due to pituitary masses on hs-CRP levels.<h4>Methods</h4>We retrospectively examined the association between GH secretion, assessed using GH-releasing peptide-2, and serum hs-CRP levels before and a year…

  96. 141.

    Nakagawa Y, Taki K. · 2024 · PMID 39027638

    Down syndrome (DS) is associated with several endocrine disorders, including diabetes, obesity, and primary hypogonadism. Here, we present a man with DS who manifested with atypical hypogonadotropic hypogonadism and in whom weight loss resulted in the improvement of hypothalamic GH deficiency. A 27-year-old man with DS and severe obesity was admitted for hypoxia resulting from obesity hypoventilation syndrome. Laboratory tests showed normal levels of LH and FSH despite low testosterone and free…

  97. 142.
  98. 143.

    2022

    Abstract <h4>Background</h4> Growth hormone (GH) deficiency, a common endocrine deficit in non-functioning pituitary tumors, causes visceral obesity and fatty liver and increases cardiovascular event risks. High-sensitivity C-reactive protein (hs-CRP) has been used as a useful marker to estimate cardiovascular event risks. Because GH supplementation therapy was reported to decrease serum hs-CRP levels in GH deficient patients, inflammatory processes might be activated in GH deficient state, howe…

  99. 144.

    Seki Y, Ichihara A. · 2021

    Abstract Introduction: Growth hormone (GH) deficiency, the most common hormone deficit complicated with pituitary tumors, is associated with higher mortality and cardiovascular events. Inflammation, as measured by high-sensitivity C-reactive protein (hs-CRP), has been reported to be associated with cardiovascular events. However, the association between hs-CRP and GH deficiency is still unknown. We retrospectively evaluated the association between serum hs-CRP levels and GH secretion in patients…

  100. 145.

    Yuen KCJ, Johannsson G, Ho KKY, Miller BS, Bergada I, Rogol AD. · 2023 · PMID 37052176

    Growth hormone deficiency (GHD) is a clinical syndrome that can manifest either as isolated or associated with additional pituitary hormone deficiencies. Although diminished height velocity and short stature are useful and important clinical markers to consider testing for GHD in children, the signs and symptoms of GHD are not always so apparent in adults. Quality of life and metabolic health are often impacted in patients with GHD; thus, making an accurate diagnosis is important so that appropr…

  101. 146.

    Gómez-Guerrero NA, González-López NM, Zapata-Velásquez JD, Martínez-Ramírez JA, Rivera-Monroy ZJ, García-Castañeda JE. · 2022 · PMID 36340120

    Peptides are very diverse molecules that can participate in a wide variety of biological processes. In this way, peptides are attractive for doping, since these molecules can activate or trigger biological processes that can improve the sports performance of athletes. Peptide molecules are found in the official World Anti-Doping Agency lists, mainly in sections S2, S4, and S5. In most cases, these molecules have a very short half-life in the body and/or are identical to natural molecules in the…

  102. 147.

    Okada N, Nakagawa T, Murahashi N, Kurosu T, et al. · Endocrine journal · 2026 · PMID 42732957

    In Japan, the Corticotropin-releasing hormone (CRH) stimulation test is widely used to evaluate secondary adrenal insufficiency (SAI); however, the insulin tolerance test (ITT) is sometimes required to assess hypothalamic dysfunction. This study aimed to identify the clinical conditions in which the ITT is necessary in addition to CRH testing. We retrospectively analyzed 69 patients who underwent both tests between August 2015 and December 2024. Forty-three patients with insufficient cortisol re…

Case Reports

1
  1. 148.

    Kimura T, Shimatsu A, Arimura H, Mori H, et al. · Endocrine journal · 2010 · PMID 20431231

    The insulin-induced hypoglycemia test (insulin tolerance test: ITT) and corticotropin-releasing hormone (CRH) test are used to examine the activities of the hypothalamo-pituitary-adrenal (HPA) axis. Growth hormone-releasing peptide-2 (GHRP-2), a potent GH secretagogue, also stimulates adrenocorticotropin (ACTH) secretion. To evaluate the role of GHRP-2 in assessing the HPA axis, we examined 6 patients with various hypothalamo-pituitary disorders, and measured ACTH and cortisol responses during p…

Curated sources on file

1
  1. 1.

Continue reading